Dr. Leo Luznik
Professor of Oncology at the John Hopkins University School of Medicine in Baltimore, USA.
Attending physician at the Division of Hematologic malignancies and BMT of the Department of Oncology.
Dr. Luznik earned his MD degree from the University of Zagreb School of Medicine, Zagreb, Croatia. He completed his postdoctoral Fellowship at the Department of Medicine of the University of California, San Diego.
He had Residency in Department of Medicine of the University of Arizona College of Medicine, Clinical Fellowship in Oncology and in Hematology at the Department of Oncology of the John Hopkins University School of Medicine, Baltimore.
Dr. Luznik is a Faculty Member of the Immunology Graduate Program and Pathobiology Graduate Program at The Johns Hopkins University.
Dr. Luznik's clinical interests are focused on the translation of the concepts developed in the laboratory to early phase clinical trials. He currently leads the multi-institutional clinical trial using high-dose cyclophosphamide as single-agent short course GVHD prophylaxis. As a part of this clinical trial, his laboratoty is also conducting a systematic study of the correlates of T-cell immune recovery with the goal of identifying critical mechanisms behind the unique ability of high-dose cyclophosphamide to prevent acute and chronic GVHD.
He is a member of several national and international hematology societies. He is Editorial Board member of the journal of Transplantation and Cellular Therapy and has published many research articles in peer-reviewed journals.
